National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Kingston, Ontario, Canada.
Int J Gynecol Cancer. 2010 Aug;20(6):945-52. doi: 10.1111/IGC.0b013e3181dd0110.
The prognostic relevance of uncommon epithelial ovarian cancer (EOC) histological subtypes remains controversial. The Gynecologic Cancer InterGroup (GCIG) initiated this meta-analysis to assess the relative prognosis of women with a diagnosis of rare EOC histologies from completed, prospectively randomized studies performed by cooperative GCIG study groups.
Studies eligible for analysis included first-line treatment of at least 150 patients with stage III/IV EOC treated with a platinum/taxane-based regimen. Collaborating groups were to provide patient-level data. Serous acted as the reference histology, and a proportional hazards model was used to estimate the relative rate of progression or death.
Data on 8704 women with stage III/IV EOC from 7 randomized trials were included in these analyses. Two hundred twenty-one patients (2.5%) had clear cell carcinoma; 264 (3.0%), mucinous; and 36 (0.4%), transitional cell. The mean age of patients with serous histology was greater than those with mucinous (4.1 years) and clear cell (2.6 years, P < 0.001). Mucinous, clear cell, and transitional cell tumors were more likely to be completely resected than serous (P < 0.05). When controlling for age and residual disease, mucinous and clear cell tumors had shorter times to progression (hazards ratio [HR], 2.1; 95% confidence interval [CI], 1.8-2.4 and HR, 1.6; 95% CI, 1.4-1.9, respectively) and death (HR, 2.7; 95% CI, 2.3-3.1 and HR, 2.2; 95% CI, 1.8-2.6, respectively) compared with serous. The median overall survival for serous, clear cell, mucinous, and endometrioid histologies were 40.8, 21.3, 14.6, and 50.9 months.
Mucinous and clear cell carcinomas are independent predictors of poor prognosis in stage III/IV EOC. Studies targeting these rare histological subtypes are warranted and will require significant intergroup collaboration.
少见的卵巢上皮癌(EOC)组织学亚型的预后相关性仍存在争议。妇科癌症协作组(GCIG)发起了这项荟萃分析,以评估罕见 EOC 组织学诊断的女性的相对预后,这些女性来自由 GCIG 协作组进行的已完成的前瞻性随机研究。
有资格进行分析的研究包括一线治疗至少 150 名接受铂类/紫杉烷类方案治疗的 III/IV 期 EOC 患者。协作组应提供患者水平的数据。浆液性作为参考组织学,使用比例风险模型估计进展或死亡的相对风险率。
7 项随机试验中纳入了 8704 名 III/IV 期 EOC 患者的数据。221 名患者(2.5%)患有透明细胞癌;264 名(3.0%)患有黏液性癌;36 名(0.4%)患有移行细胞癌。浆液性组织学患者的平均年龄大于黏液性(4.1 岁)和透明细胞性(2.6 岁,P < 0.001)。黏液性、透明细胞性和移行细胞性肿瘤比浆液性更有可能完全切除(P < 0.05)。在控制年龄和残留疾病后,黏液性和透明细胞性肿瘤的进展时间更短(风险比[HR],2.1;95%置信区间[CI],1.8-2.4 和 HR,1.6;95%CI,1.4-1.9,分别)和死亡(HR,2.7;95%CI,2.3-3.1 和 HR,2.2;95%CI,1.8-2.6,分别)与浆液性相比。浆液性、透明细胞性、黏液性和子宫内膜样组织学的中位总生存期分别为 40.8、21.3、14.6 和 50.9 个月。
黏液性和透明细胞癌是 III/IV 期 EOC 不良预后的独立预测因素。针对这些罕见组织学亚型的研究是合理的,需要进行大量的组间合作。